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BACKGROUND: Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor and rapamycin analogue that is approved for
treating advanced renal cell carcinoma (RCC). It is being actively evaluated in clinical trials for melanoma. The mTOR inhibitors are
also immunosuppressants and are used clinically to prevent rejection following solid-organ transplant. Novel immunotherapies are
being actively developed for immunoresponsive tumours, such as RCC and melanoma.
METHODS: Immune-modulating effects of temsirolimus were characterised when used in combination with cancer vaccines targeting
RCC (RENCA) and melanoma (B16). Cancer vaccines were recombinant tumour-specific proteins (CA9 or gp100), and
recombinant heat shock protein (HSP; hsp110) served as the immune adjuvant.
RESULTS: In murine models, temsirolimus enhanced the anti-tumour activity of cancer vaccines used to treat established RENCA and
B16 tumours. A tumour prevention model established that the enhanced anti-tumour activity associated with temsirolimus was
immune mediated. In mice treated with an HSP-based anti-tumour vaccine, temsirolimus-treated CD8 T cells had greater interferon-g
and cytotoxic T-cell responses when compared with mice treated with vaccine alone. Temsirolimus also enhanced the formation of
CD8 memory cells following administration of HSP-based cancer vaccine.
CONCLUSION: These results provide a rationale for combining mTOR inhibitor with immunotherapy when treating immunoresponsive
tumours.
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The mammalian target of rapamycin (mTOR) is a pivotal regulator
of cell proliferation. (Thomson et al, 2009) The mTOR protein
integrates diverse signals originating from growth factors, energy
status, and cellular stress, and promotes mRNA translation and
cell proliferation. Therefore, inhibition of mTOR function has
broad anti-proliferative effects. Temsirolimus and evirolimus
are mTOR inhibitors that are currently approved for treatment
of advanced renal cell carcinoma (RCC), and both agents are being
actively investigated in clinical trials for a large number of
malignancies. The rationale for using mTOR inhibitors to treat
malignancies has focused on the direct, growth-inhibitory effects
of mTOR inhibitors.
However, mTOR inhibitors are expected to have important
immune-modulating effects. Rapamycin is the prototypic mTOR
inhibitor, and is widely used to suppress the immune system and
prevent rejection of solid-organ transplants. For this reason, recent
reports attributing immune-stimulating effects to mTOR inhibi-
tion are surprising. These reports directly show that rapamycin
can enhance vaccines targeting bacteria (Jagannath et al, 2009) or
virus (Araki et al, 2009) in mouse models. Therefore, it may be
possible to use mTOR inhibitors to enhance vaccines targeting
cancers. Understanding the immune effects of mTOR inhibition is
particularly relevant for immunoresponsive diseases, such as RCC
and melanoma, for which novel cancer vaccines are being actively
developed. The mTOR inhibitors are approved for advanced RCC
patients; therefore, the possibility of combing a new cancer vaccine
with an established therapy that has unexpected immunostimula-
tory properties is attractive.
We investigated the effects of temsirolimus when used in
combination with heat shock protein (HSP)-based anti-tumour
vaccines in experimental tumour models for RCC and melanoma.
The HSPs are immune adjuvants that are capable of binding
tumour antigens and interacting with antigen-presenting cells to
mediate a CD8 T-cell response (Udono et al, 1994; Todryk et al,
2000; Castelli et al, 2001; Matsutake and Srivastava, 2001). In our
survey of the immune effects mediated by the combination of
cancer vaccine and mTOR inhibition, temsirolimus had
both immunosuppressive and immunostimulatory properties.
Temsirolimus decreased the proliferation of activated T cells,
increased the relative abundance of regulatory T cells, and
suppressed dendritic cell (DC) function. However, temsirolimus
enhanced the activation of effector CD8 T cells and development of
memory CD8 T cells. The net effect of temsirolimus was to enhance
the anti-tumour response to HSP-based tumour vaccines.
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Mice and cell lines
Wild-type C57BL/6 and BALB/C mice, 6–8 weeks old, were
purchased from NCI (Frederick, MD, USA) and housed under
pathogen-free conditions. Pmel-1 mice that carry T-cell receptor
(TCR) transgene specific for the mouse homologue (pmel-17) of
human glycoprotein gp100 were purchased from Jackson Labora-
tory (Bar Harbor, ME, USA). RENCA, a murine RCC line, stably
transduced to express human CA9 (RENCA-CA9) was a gift from
Dr Arie Belldegrun (University of California, Los Angeles). Human
gp100-transduced B16 (B16-gp100), a murine melanoma line,
was kindly provided by Dr Alexander Rakhmilevich (University
of Wisconsin). These cells were maintained in Dulbecco’s modified
Eagle’s medium and RPMI 1640, supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Life Technologies, Grand
Island, NY, USA), 2mmoll
 1 of L-glutamine, 100Uml
 1 of
penicillin, and 100mgml
 1 of streptomycin. The in vitro tumour
cell growth studies are described in the supplemental methods. All
animal studies were reviewed and approved by the Institutional
Animal Care and Use Committee.
Antibodies and reagents
Mouse monoclonal antibodies (mAbs) were purchased and used to
bind CD8-a (53–6.7 PE-Cy5.5 conjugated, Biolegend, San Diego,
CA, USA); Thy1.1 (OX-7, FITC conjugated, Biolegend); FoxP3
(150D, eBioscience, San Diego, CA, USA); CD62L (MEL-14,
Biolegend); interferon (IFN)-g (FITC conjugated, BD Biosciences
Pharmingen, San Jose, CA, USA); DC marker CD11c (HL3, PE
conjugated, BD Biosciences Pharmingen); MHC class I molecule
H-2K
b (AF6-88.5, PE conjugated, BD Biosciences Pharmingen);
MHC class II molecule I-A/I-E (2G9, FITC conjugated, BD
Biosciences Pharmingen); co-stimulatory molecules CD80
(16-10A1, PE conjugated, BD Biosciences Pharmingen); and CD86
(GL1, PE conjugated, BD Biosciences Pharmingen). Immunostain-
ing is described in supplemental material. Recombinant human
interleukin (IL)-2 was purchased from Novartis Pharmaceuticals
(Emeryville, CA, USA). The cDNA for mouse hsp110, human CA9 (a
gift from Dr Arie Belldegrun), and human gp100 (a gift from
Dr Nicholas Restifo, National Cancer Institute) were cloned into
pBacPAK-his vector (BD Biosciences Clontech, Mountain View, CA,
USA), and recombinant proteins were produced using the BacPAK
baculovirus system according to the manufacturer’s recommenda-
tions. CellTrace 5-(and 6-)carboxyfluorescein diacetate succinimidyl
ester (CFSE) cell proliferation kit was purchased from Molecular
Probes (Eugene, OR, USA). Temsirolimus and rapamycin were
purchased from LC Laboratories (Woburn, MA, USA).
Anti-tumour studies in mice
The HSP-based anti-tumour vaccines were generated by incubat-
ing and non-covalently complexing recombinant proteins; hsp110
was combined with gp100 or CA9 at an equal molar ratio as
previously described (Wang et al, 2003, 2008). In the tumour
treatment study, BALB/C mice were injected intradermally (i.d.)
with vaccine consisting of 2 10
5 RENCA-CA9 cells on day
0. C57BL/6 mice were injected i.d. with vaccine consisting of
2 10
5 B16-gp100 cells on day 0. Starting day 10, mice were treated
based on group assignment (five mice per group): group 1: control
mice were treated with PBS (subcutaneously, s.c.) on days 10 and
17. Group 2: vaccine (25mg gp100 or CA9 complexed with an equal
molar ratio of hsp110) was injected i.d. on days 10 and 17. Group
3: temsirolimus (15mg) was injected intraperitoneally (i.p.) on days
11–24. Group 4: group receiving vaccine plus temsirolimus was
treated as described for groups 2 and 3. Tumours were measured
every 3 days using an electronic caliper, and tumour volume was
calculated as (shortest diameter
2   longest diameter/2). The
tumour prevention study was performed similarly, except a single
vaccine dose (day 0) was administered, temsirolimus was injected
daily on days 8–32, and tumour cells were implanted on day 150.
In vitro T-cell proliferation
For the [
3H] thymidine incorporation assay, lymph nodes were
harvested from naive C57 BL/6 or Pmel-1 mouse. In all, 3 10
5
cells per well were cultured in 96-well plates and stimulated, with
or without mTOR inhibitors, for 72h. C57 BL/6 lymphocytes were
stimulated with anti-CD3 and anti-CD28 mAb, and Pmel-1
lymphocytes were stimulated with gp100 peptide. DNA synthesis
was determined by incubation for 16h with 1mCi [
3H]thymidine
(Amersham Biosciences, Piscataway, NJ, USA).
For the CFSE dilution assay, lymphocytes were harvested and
treated as described above. The cells were labelled with 5mM CFSE,
incubated at 371C for 20min, washed, and re-suspended in
complete culture medium (RPMI 1640, 10% fetal calf serum,
2mmoll
 1 L-glutamine, 100Uml
 1 penicillin/streptomycin). Lym-
phocyte proliferation was assessed by flow cytometric analysis of
CFSE dilution while gating on CD4 or CD8. To study lymphocyte
proliferation in response to DC stimulation, bone marrow (BM)
DCs were pulsed with antigens for 2h, washed, treated with mTOR
inhibitors for 2h, and then washed again. Lymphocytes were
harvested from Pmel-1 mice. CD8 T cells were purified by negative
selection using mouse CD8 cell recovery column kit (Cedarlane,
Ontario, Canada). Antigen-pulsed DC and CFSE-labelled lympho-
cytes were mixed at 1:10 ratio, and cultured for 48–72h.
Lymphocyte proliferation was assessed by flow cytometric analysis
of CFSE dilution.
Assays for T-cell function
The assays for T-cell function have been described previously
(Wang et al, 2008). The ELISPOT assay, the in vivo CTL assay, and
the intracellular IFN-g staining are briefly described in the
supplemental material.
Adoptive transfers and treatment
To study T-cell memory, 3 10
4 CD8
þ/Thy1.1
þ lymphocytes
from naı ¨ve Pmel-1 mice were adoptively transferred intravenously
to C57BL/6 mice on day  1. On day 0, mice were immunised
(complex of hsp110 and gp100) i.d., injected daily (i.p.) with
temsirolimus (15mgml
 1 in 100ml PBS) from days 8 to 32, or
treated with both. To assess the memory response, mice were
re-challenged with vaccine on day 33. Spleen and lymph nodes
were collected on days 18, 32, and 39. CD8, Thy1.1, and IFN-g-
positive cells were analysed by flow cytometry.
Preparation of DCs from BM and characterisation of
DC markers
The BMs were harvested from femurs and tibias, and treated with
red cell lysis buffer, washed, and plated at a density of 1 10
6 cells
per ml in 12-well plates in RPMI 1640 containing 10% FBS
and 10ngml
 1 of recombinant mouse GM–CSF (eBioscience).
Cells were fed every 2 days and harvested on days 7–9. In the
culture, 75–90% of the cells were CD11c positive.
The BM DCs were stimulated for 24h in complete medium
with or without temsirolimus and washed 3 times with PBA (PBS
with 0.1% bovine serum albumin (BSA) and 0.01% sodium azide).
For FACS analysis, cells (3–5 10
5) were suspended in 100ml PBS
with 0.3% BSA and 0.05% sodium azide, and were stained with
antibodies for 30min on ice. After incubation, the cells were
washed, and the fluorescence was measured by a FACScan (Becton,
Franklin Lakes, NJ, USA). For each sample, fluorescence data from
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s10000 cells were collected, and positive cells were expressed as the
percent of total events.
RESULTS
Effect of cancer vaccine and temsirolimus on tumour
growth
The HSP-based vaccines consisting of a non-covalent complex of
recombinant HSP and recombinant tumour antigen are effective
for stimulating anti-tumour immunity in animal models (Wang
et al, 2003; Kim et al, 2007). However, HSP-based vaccines have
only a modest effect on growth of well-established murine
tumours. The immune-modulating effects of temsirolimus were
evaluated using an experimental model where vaccine therapy
alone is insufficient. Before starting treatment, tumours that grow
aggressively and require sacrifice of animals within B20 days were
grown s.c. for 10 days until they were clearly palpable (Figure 1A).
The average RENCA tumour was 49mm
3 and the average B16
tumour was 67mm
3 on day 10. In a RCC model, RENCA tumours
expressing CA9 were treated with tumour vaccine (hsp110þCA9)
and temsirolimus (Figure 1B). Temsirolimus alone produced some
inhibition of tumour growth, indicating that temsirolimus has
direct anti-tumour effect against RENCA. However, the combina-
tion of tumour vaccine and temsirolimus eradicated the tumour in
all animals.
In a murine melanoma model, B16 melanoma cells expressing
gp100 were implanted 10 days before starting treatment with
tumour vaccine (hsp110þgp100) and temsirolimus (Figure 1C).
The combination of vaccine and temsirolimus was more effective
in inhibiting tumour growth than either therapy alone. The
inhibition of tumour growth may have been mediated, in part, by
direct cytotoxic effect as well as indirect anti-tumour immune
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Figure 1 Combination therapy with HSP-based tumour vaccine and temsirolimus inhibits the growth of established tumours in models of renal cell
carcinoma and melanoma. (A) A tumour treatment model was used to assess anti-tumour activity. After 10 days of s.c. implantation of syngeneic tumour
lines, mice (five mice per group) were treated with PBS (control), tumour vaccine (days 10 and 17), temsirolimus (days 11–16, 18–23), or both, and tumour
growth was monitored. (B) In a renal cell carcinoma model, RENCA-CA9 cells were implanted into BALB/C mice. The tumour vaccine was a non-covalent
complex of recombinant hsp110 and CA9. Each line represents tumour growth in a single animal (B and C). P-values are provided comparing various groups
using the repeated measures ANOVA. (C) In a melanoma model, B16-gp100 cells were implanted into B6 mice. The tumour vaccine was a non-covalent
complex of recombinant hsp110 and gp100. Representative results are shown from at least two independent experiments.
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seffects. Therefore, to assess the direct anti-tumour effects of
temsirolimus on RENCA and B16, both cell lines were cultured
in the presence of varying concentrations of temsirolimus
(Figure 2A). RENCA was sensitive to temsirolimus; however, B16
was unaffected by concentrations of temsirolimus several folds
higher than expected in mouse serum (Guba et al, 2005),
suggesting that the inhibition of these tumours in vivo is at least,
in part, immune mediated.
To firmly establish a temsirolimus-mediated immune mechan-
ism for inhibition of tumour growth, a tumour prevention model
was used (Figure 2B). In the B16 melanoma model, mice (six per
group) were treated with a single dose of tumour vaccine with or
without temsirolimus, and challenged with B16 tumour cells after
more than 100 days following the last temsirolimus administration.
Therefore, temsirolimus could not have had any direct cytotoxic
effects on the B16 tumours. Administration of vaccine alone had a
significant inhibitory effect on the growth of B16 tumours
(Figure 2C). However, the administration of both vaccine and
temsirolimus prevented the growth of tumour in all mice, and
animals remained tumour free during over 60 days of observation.
Therefore, temsirolimus augments the anti-tumour immunity
induced by HSP-based cancer vaccines.
As a class, mTOR inhibitors are well-characterised immune
suppressors. Therefore, these observations are surprising. In the
following experiments, the immunostimulatory and immunosup-
pressive properties of temsirolimus were characterised in our model.
Immunosuppressive effects
Effect of temsirolimus on T-cell proliferation. Temsirolimus is
an analogue of the classic mTOR inhibitor, rapamycin. Both
temsirolimus and rapamycin inhibited the proliferation of
activated T cells in vitro (Figures 3A and B). The [
3H] thymidine
incorporation assay showed that mTOR inhibition decreased
proliferation of bulk T cells. The CFSE dilution assays were then
performed to assess the effects of mTOR inhibition on specific
populations of T cells (Figure 3C). Temsirolimus and rapamycin
inhibited the proliferation of activated CD8 T cells and CD4 T cells
in a dose-dependent manner in vitro. However, the in vivo effects
were less pronounced (Figure 3D). Following treatment of B6 mice
with temsirolimus for 24 days, the percent of lymphocytes that
were CD8þ was unchanged by temsirolimus. The percent of CD4
lymphocytes was decreased in all groups that received temsir-
olimus; however, the percent of CD4 cells that were also FoxP3þ
was increased by temsirolimus. Therefore, temsirolimus increased
the relative abundance of regulatory CD4 cells.
Effect of temsirolimus on DCs. The mTOR pathway is involved
in many key functions performed by DCs (Thomson et al, 2009).
Others have documented that during LPS stimulation, mTOR
inhibition can decrease the expression of DC markers that are
critical to its function (Hackstein et al, 2002; Monti et al, 2003).
In our study, baseline DC markers were essentially unaffected
by varying concentrations of temsirolimus applied for 24h
(Figure 4A). However, when generating anti-tumour immunity,
the ability to stimulate T cells is ultimately the most critical DC
function. Therefore, DCs were stimulated with hsp110þgp100 and
then treated with temsirolimus (Figure 4B). These DCs were then
used to stimulate CD8 T cells purified from Pmel-1 transgenic
mice, which carry a rearranged TCR that recognises a gp100
epitope (amino acids 25–33) presented by H2-D
b MHC class I
molecules. Temsirolimus treatment decreased the ability of DCs to
stimulate Pmel-1 CD8 T-cell proliferation.
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Figure 2 Temsirolimus can have a direct anti-proliferative effect on
the tumour; however, temsirolimus can also prevent tumour growth
by enhancing anti-tumour immunity. (A) Direct anti-tumour effects of
temsirolimus were assessed for RENCA and B16 cell lines in vitro.
Data show mean and s.e.m. values. Representative results are shown
from at least three experimental repeats. (B) In a murine tumour
prevention model, B6 mice (six mice per group) were treated with PBS
(day 0), tumour vaccine (day 0), or tumour vaccine plus temsirolimus (days
8–32). (C) Mice were challenged with B16-gp100 cells, and tumour
growth was monitored. The tumour vaccine was a non-covalent
complex of recombinant hsp110 and gp100. Mean tumour growth
and s.e.m. are provided, and P-values were determined using
repeated measures ANOVA. CM¼complete medium, SF¼serum-free
medium.
Figure 3 Temsirolimus decreases proliferation of activated T cells and increases the percent of CD4 cells that express FoxP3. (A and B) Proliferation of
activated lymphocytes was assessed in vitro by monitoring [
3H] thymidine incorporation. B6 lymphocytes were stimulated with anti-CD3 and anti-CD28
mAb (A), and Pmel-1 lymphocytes were stimulated with gp100 peptide (B). Lymphocytes were stimulated in the presence of varying concentrations of
temsirolimus or rapamycin, and proliferation was monitored. (C) Proliferation of activated CD4 or CD8 T cells was assessed in vitro with CFSE dilution
assays. B6 lymphocytes were labelled with CFSE and stimulated with anti-CD3 and anti-CD28 mAb in the presence of varying concentrations of
temsirolimus or rapamycin. The CFSE profiles were monitored after gating on CD8 or CD4. (D) In vivo effects of temsirolimus on CD4 or CD8 T cells were
assessed. B6 mice (five mice per group) were treated daily with temsirolimus for 24 days, two doses of vaccine (complex of hsp110 and gp100), or both.
CD4 and CD8 lymphocytes were assessed by flow cytometry. FoxP3 staining was quantified while gating on CD4. Data show mean and s.e.m. values
Representative results are shown from at least two independent experiments.
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sImmunostimulatory effects
Activation of CD8 T cells. The effect of temsirolimus on T-cell
activation was evaluated both in vitro and in vivo. Splenocytes
from Pmel-1 mice were harvested and treated with gp100 peptide
with or without temsirolimus (Figure 5A). Splenocytes expressing
CD8 and staining for IFN-g were increased in the group treated
with temsirolimus. The IFN-g response was also measured with
an ELISPOT assay (Figure 5B); treatment of B6 mice with
hsp110þgp100 produced a gp100-specific IFN-g response that
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swas significantly increased by temsirolimus. Interleukin-2 is an
immunostimulatory cytokine that can enhance a cellular immune
response and was included for comparison. The combination of
vaccine and temsirolimus produced a greater IFN-g response than
the combination of vaccine and IL-2. Finally, an in vivo CTL assay
was performed (Figure 5C). Temsirolimus increased the killing
of gp100 peptide-treated target cells. These results show that
temsirolimus enhances the activation and function of effector
T cells stimulated with an HSP-based anti-tumour vaccine.
Memory T-cell response. Memory T cells are critical for genera-
ting effective anti-tumour immunity. The tumour prevention study
presented in Figure 2B and C suggests that the combination of
cancer vaccine and temsirolimus is highly effective in generating
BMDC tem for 24 hrs DC markers: MHC I, MHC II, B7.1, and B7.2
Gated on
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+
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Figure 4 Treatment with temsirolimus has minimal effect on baseline expression of DC markers; however, temsirolimus decreases the capacity of DCs to
stimulate T-cell proliferation. (A) To assess baseline DC markers, BM-derived DCs were treated in vitro for 24h with varying doses of temsirolimus. The DCs
were examined by flow cytometry while gating on CD11c. (B) To assess DC function, BM-derived DCs were stimulated with vaccine (complex of hsp110
and gp100) and then treated with temsirolimus (50ngml
 1). These DCs were then used to stimulate CD8 T cells purified by negative selection from Pmel-1
lymphocytes. Proliferation of Pmel-1 T cells was assessed by monitoring CSFE dilution while gating on CD8. Representative results are shown from at least
three independent experiments.
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the combination therapy, Pmel-1 lymphocytes were adoptively
transferred into B6 mice (Figure 6A). The donor lymphocytes were
stimulated by treating the B6 mice with hsp110þgp100 (day 0).
Temsirolimus was administered during the transition from effector
phase to memory phase (days 8–32). Donor-derived lymphocytes
were monitored by flow cytometry while gating on Thy1.1; by day
32, all surviving donor-derived lymphocytes were considered
memory cells.
To assess the ability of memory cells to re-activate, percent of
donor-derived lymphocytes that stain for IFN-g was assessed
(Figure 6B). Temsirolimus had no effect on percent of donor cells
staining for IFN-g in samples collected before repeat challenge with
vaccine (i.e., days 18 and 32). However, following re-stimulation
on day 33, the percent of donor cells collected on day 39 that
stained for IFN-g was highest in the group treated with both
vaccine and temsirolimus (Figure 6C). Interestingly, proliferation
of CD8 T cell following re-stimulation was not significantly
different between any of the treatment groups and the control
group, suggesting that temsirolimus enhances memory CD8 T-cell
function rather than proliferation. Consistent with this possibility,
a higher percent of the memory cells stimulated by the cancer
vaccine in the presence of temsirolimus was positive for CD62L,
which is a marker for the more effective central memory cells.
DISCUSSION
The mTOR protein has a critical role in integrating diverse
environmental signals that ultimately affect cell growth and
proliferation. Inhibition of mTOR function has a large number
of cellular effects that include inhibition of proliferation.
Temsirolimus is a rapamycin analogue and a potent mTOR
inhibitor that is FDA approved for the treatment of advanced RCC.
We characterised effects of temsirolimus when used in combina-
tion with a novel cancer vaccine. It is surprising that temsirolimus
can enhance anti-tumour immunity, as rapamycin is widely used
in the clinic to suppress the immune system following solid-organ
transplantation. In an experimental murine model of RCC
(RENCA), the combination of an HSP-based cancer vaccine and
temsirolimus was more effective against established tumours than
either agent alone. This observation was confirmed in an
experimental murine model of melanoma (B16), which is another
classic immunoresponsive malignancy. In both models, untreated
animals were needed to be killed B20 days following tumour
implantation. To make the study rigorous, tumours were allowed
to grow for 10 days until they were palpable and had an established
vascular supply before starting treatment.
Temsirolimus had direct anti-proliferative effects on RENCA
cells in vitro. However, there was no direct effect on the growth of
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Figure 5 Temsirolimus enhances the activation of T cells. (A) The stimulation of antigen-specific IFN-g response from CD8 T cells was examined in vitro.
Pmel-1 splenocytes were harvested, stimulated with gp100 peptide, and examined for IFN-g staining by flow cytometry while gating on CD8. (B) The in vivo
gp100-specific immune response was measured using an ELISPOT assay. B6 mice were treated with vaccine (complex of hsp110 and gp100), temsirolimus
(daily for 14 days), or both. Treatment with IL-2 (5 10
4U per mouse daily for 14 days) was included for comparison. (C) T-cell activation and killing ability
were assessed using an in vivo cytotoxic T-lymphocyte assay. Pmel-1 lymphocytes were adoptively transferred into B6 mice. The mice were treated once
with cancer vaccine, with or without 7 days of temsirolimus. Splenocytes from naive mice pulsed with murine gp100 peptide were fluorescently labelled and
used as target cells. Splenocytes and lymphocytes were harvested after 14h and analysed by flow cytometry. Representative results are shown from at least
two independent experiments. IL-2¼interleukin-2.
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sB16 cells, suggesting that immune modulation may have produced
the anti-tumour effects seen in the animal studies. To provide
definitive evidence that mTOR inhibition can positively modulate
an immune response, a tumour prevention model was used to
isolate the immune effects of combination therapy. Mice were
challenged with tumour cells for more than 100 days following
treatment with cancer vaccine and temsirolimus. As the tumour
cells were never directly exposed to temsirolimus, all anti-tumour
effects could be attributed to immunostimulation. The combina-
tion therapy completely inhibited tumour growth, whereas
treatment with cancer vaccine alone did not. Therefore, temsir-
olimus enhanced anti-tumour immunity.
The anti-tumour studies demonstrated that the net effect of
immune modulation with mTOR inhibition was to enhance the
cancer vaccine. However, mTOR inhibitors are known to have both
immune-stimulating and immune-suppressing effects. To better
understand these opposing functions, the immune effects of mTOR
inhibition were characterised in our model. A detailed under-
standing of immune modulation may shed light on the mechanism
of action of pharmacological mTOR inhibition, and identify
strategies to enhance a particularly mTOR function and achieve
varied clinical objectives.
Temsirolimus and rapamycin inhibited the proliferation of both
activated CD8 and CD4 T cells in vitro. This observation is
consistent with previous reports that rapamycin directly inhibits
T-cell activation and proliferation (Mondino and Mueller, 2007;
Song et al, 2007). In our study, the in vivo effects of mTOR
inhibition differed for CD8 and CD4 T cells. When temsirolimus
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Figure 6 Temsirolimus enhances memory T-cell response by producing centrally homing memory T cells capable of enhanced IFN-g response on
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(five mice per group) on day  1. On day 0, mice were treated with vaccine (complex of hsp110 and gp100). Temsirolimus was administered during the
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(C) From the same experiment, the mean and s.e.m. values for the donor-derived IFN-g response are provided (left panel). To assess proliferation of donor-
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swas administered to mice, the percent of CD8 lymphocytes in
lymph nodes did not change, whereas the percent of CD4
lymphocytes decreased. CD4 lymphocytes include both effector
and regulatory lymphocytes. Despite an overall decrease in CD4
lymphocytes, the percent of CD4 lymphocytes expressing FoxP3
increased in groups that received temsirolimus. This observation is
consistent with reports that regulatory T cells are less sensitive to
the anti-proliferative effects of mTOR inhibition (Battaglia et al,
2006; Segundo et al, 2006). In transplant patients treated with
mTOR inhibition, an increase in regulatory T cells is believed to be
an important mechanism for immune suppression. Therefore,
the effects of mTOR inhibition on lymphocyte proliferation and
regulatory T-cells are expected to favour immune suppression.
However, effector T cells generated in vivo during treatment
with mTOR inhibitor had greater activity as measured using an
ELISPOT assay. In a confirmatory study, the increased IFN-g
response was localised to CD8 T-cells. Furthermore, temsirolimus
enhanced in vivo killing by cytotoxic T lymphocytes. These
results suggest that the primary immune response generated by the
cancer vaccine was enhanced by temsirolimus. It is possible that
the regulatory T cells that increase during temsirolimus treatment
ultimately suppress the CD8 T cell response; however, another
possibility is that the increase in regulatory T cells is a negative
feedback response to the enhanced cytotoxic T-cell function.
Previous reports do not produce a clear picture of the effects of
mTOR inhibition on DC function. For example, rapamycin has
been shown to suppress DC maturation by downregulating the
IL-4 receptor complex and decreasing the production of IL-2 and
tumour necrosis factor (Hackstein et al, 2003). Also, human
DCs matured from monocytes in the presence of rapamycin had
decreased ability to take up antigen, including decreased
endocytosis and phagocytosis (Monti et al, 2003). However, other
recent reports suggest that mTOR inhibition may enhance the
innate immune response in DCs (Weichhart et al, 2008) and
stimulate autophagy, which can enhance antigen presentation
(Jagannath et al, 2009). We found no evidence that temsirolimus
promotes anti-tumour immunity through its effects on DCs.
Temsirolimus did not change the expression of baseline DC
markers. In fact, BM-derived DCs stimulated with cancer vaccine
and temsirolimus had decreased ability to stimulate CD8 T cell
when compared with DCs stimulated with vaccine alone. The
mTOR inhibition had a suppressive effect on overall DC function.
Therefore, the effects of mTOR inhibition on DCs do not explain
the enhanced anti-tumour immunity seen in our models.
We also characterised the effects of temsirolimus on CD8
memory cell formation. To minimise the effects of temsirolimus
during the T-cell expansion phase, temsirolimus was started
during T-cell contraction. This treatment schedule focuses
the effects of temsirolimus on the transition from effector CD8
T cells to memory cells. Mice were re-stimulated with tumour
antigen 33 days following primary vaccination when all transferred
T cells should be long-lived memory cells. Samples collected 7 days
after the re-stimulation show that CD8 T cells from animals treated
with both vaccine and temsirolimus have an enhanced IFN-g
response when compared with controls; however, CD8 T-cell
proliferation was not significantly enhanced by temsirolimus. This
is consistent with a recent report that rapamycin treatment during
T-cell contraction does not alter the number of CD8 T cells,
but rather accelerates memory differentiation and produces T cells
with phenotypic characteristics of highly functioning memory
cells (Araki et al, 2009). We found that combined treatment with
cancer vaccine and temsirolimus produced memory cells with
greater CD62L expression than control treatments, indicating
that temsirolimus promotes formation of central memory, which
is associated with enhanced anti-tumour activity (Klebanoff
et al, 2005).
The RCC and melanoma are classic immunoresponsive tumours.
Novel cancer vaccines are being actively developed for these and
other malignancies. Our results provide a rationale for combining
mTOR inhibitors with novel and established immune therapies.
Temsirolimus is currently approved for the treatment of RCC, and
is therefore particularly attractive for use with cancer vaccines that
are being investigated for RCC. Future studies will need to develop
optimal dosing strategies and identify cancer vaccines that are best
suited for use with mTOR inhibitors.
Summary
Temsirolimus is an anti-neoplastic agent that is currently
approved for patient use. It has immune-modulating activity.
In animal models for studying tumour vaccines, temsirolimus
enhanced vaccine activity by enhancing effector T-cell function
and enhancing the production of CD8 memory T cells.
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